Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Xuping Xie; Jing Zou; Camila R Fontes-Garfias; Hongjie Xia; Kena A Swanson; Mark Cutler; David Cooper; Vineet D Menachery; Scott Weaver; Philip R Dormitzer; Pei-Yong Shi

doi:10.1101/2021.01.07.425740

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

bioRxiv [Preprint]. 2021 Jan 7:2021.01.07.425740. doi: 10.1101/2021.01.07.425740.

Authors

Xuping Xie¹, Jing Zou¹, Camila R Fontes-Garfias¹, Hongjie Xia¹, Kena A Swanson², Mark Cutler², David Cooper², Vineet D Menachery^{3

4}, Scott Weaver^{3

4}, Philip R Dormitzer², Pei-Yong Shi^{1

4

5

6

7}

Affiliations

¹ Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
² Pfizer, 401 N Middletown Rd., Pearl River, NY 10960, U.S.A.
³ Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, U.S.A.
⁴ Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
⁵ Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, U.S.A.
⁶ Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, U.S.A.
⁷ Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, U.S.A.

Abstract

Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N501 and Y501 viruses.

Publication types

Preprint

Abstract

Publication types

Grants and funding